Compare Moderna, Inc. (MRNA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs US Bancorp — how do they compare? Moderna, Inc. trades at $196.55 (market cap $78.65B), while US Bancorp trades at $57.07 (market cap $88.86B). The key difference: Moderna, Inc. and US Bancorp are close in size by market cap, and US Bancorp pays a 3.79% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and US Bancorp for 97 Days on average.
| MRNA | USB | |
|---|---|---|
Market Cap | $78.65B | $88.86B |
Volume | 37,373,437 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $203.46 | $65.42 |
52-Week Low | $22.36 | $45.28 |
Typical Hold Time | 59 Days | 97 Days |
Enterprise Value | $74.80B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
U.S. Bancorp (USB) trades at $56.17, down 1.95% with bearish technical signals but strong fundamentals including consistent earnings beats and a 27.61% net margin. The stock offers a $2.16 annual dividend yield with recent 3.8% increase. Analyst consensus is bullish with $69.94 price target despite near-term technical weakness.
USB presents a value opportunity with attractive P/E of 11.38 and strong profitability metrics, though investors face interest rate sensitivity and regulatory uncertainty risks. The bank's solid earnings track record and dividend growth support long-term investment case despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
